MIRA Pharmaceuticals announced that its oral ketamine analog, Ketamir-2, has demonstrated superior efficacy compared to FDA-approved treatments Gabapentin (Neurontin) and Pregabalin (Lyrica) in recent preclinical models of neuropathic pain. The company is currently conducting additional studies focusing on chemotherapy-induced and diabetic neuropathy.The development program includes plans for PTSD trials, with the company exploring government funding opportunities for this initiative. MIRA remains on schedule to submit an Investigational New Drug (IND) application by end-2024, with Phase I clinical trials slated for Q1 2025 and Phase II trials projected to commence by late 2025.

MIRA Pharmaceuticals announced that its oral ketamine analog, Ketamir-2, has demonstrated superior efficacy compared to FDA-approved treatments Gabapentin (Neurontin) and Pregabalin (Lyrica) in recent preclinical models of neuropathic pain. The company is currently conducting additional studies focusing on chemotherapy-induced and diabetic neuropathy.The development program includes plans for PTSD trials, with the company exploring government funding opportunities for this initiative. MIRA remains on schedule to submit an Investigational New Drug (IND) application by end-2024, with Phase I clinical trials slated for Q1 2025 and Phase II trials projected to commence by late 2025.